CA2867694C - A novel cholesterol metabolite, 5-cholesten, 3.beta.-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis - Google Patents

A novel cholesterol metabolite, 5-cholesten, 3.beta.-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis Download PDF

Info

Publication number
CA2867694C
CA2867694C CA2867694A CA2867694A CA2867694C CA 2867694 C CA2867694 C CA 2867694C CA 2867694 A CA2867694 A CA 2867694A CA 2867694 A CA2867694 A CA 2867694A CA 2867694 C CA2867694 C CA 2867694C
Authority
CA
Canada
Prior art keywords
subject
need
compound
25hcds
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2867694A
Other languages
English (en)
French (fr)
Other versions
CA2867694A1 (en
Inventor
Shunlin Ren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of CA2867694A1 publication Critical patent/CA2867694A1/en
Application granted granted Critical
Publication of CA2867694C publication Critical patent/CA2867694C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2867694A 2012-04-12 2013-03-15 A novel cholesterol metabolite, 5-cholesten, 3.beta.-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis Active CA2867694C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623203P 2012-04-12 2012-04-12
US201261623414P 2012-04-12 2012-04-12
US61/623,203 2012-04-12
US61/623,414 2012-04-12
PCT/US2013/031861 WO2013154752A1 (en) 2012-04-12 2013-03-15 A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS

Publications (2)

Publication Number Publication Date
CA2867694A1 CA2867694A1 (en) 2013-10-17
CA2867694C true CA2867694C (en) 2021-08-31

Family

ID=49328028

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2867694A Active CA2867694C (en) 2012-04-12 2013-03-15 A novel cholesterol metabolite, 5-cholesten, 3.beta.-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis

Country Status (20)

Country Link
US (6) US20150072962A1 (https=)
EP (2) EP3239163A1 (https=)
JP (4) JP6125610B2 (https=)
KR (1) KR102180485B1 (https=)
CN (2) CN106083976B (https=)
AU (2) AU2013246435B2 (https=)
BR (1) BR112014025081B1 (https=)
CA (1) CA2867694C (https=)
DK (1) DK2836502T3 (https=)
EA (1) EA026683B1 (https=)
ES (1) ES2641841T3 (https=)
HU (1) HUE035073T2 (https=)
IL (1) IL234892B (https=)
IN (1) IN2014KN02366A (https=)
MX (1) MX357046B (https=)
PL (1) PL2836502T3 (https=)
PT (1) PT2836502T (https=)
SI (1) SI2836502T1 (https=)
WO (1) WO2013154752A1 (https=)
ZA (1) ZA201406981B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
EA026683B1 (ru) * 2012-04-12 2017-05-31 Вирджиния Коммонвелт Юниверсити МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА
PL3639828T3 (pl) * 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
TWI547280B (zh) * 2014-04-24 2016-09-01 長弘生物科技股份有限公司 穩定醫藥組合物
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
CN107106576A (zh) * 2014-10-10 2017-08-29 弗吉尼亚联邦大学 用于因减弱的瘦蛋白活性和脂质贮积障碍中的至少一种导致的障碍的疗法的氧化胆固醇硫酸酯类
JP6784963B2 (ja) * 2014-12-24 2020-11-18 国立大学法人京都大学 ビタミンｄ３誘導体及びその薬学的用途
US20200222430A1 (en) * 2016-08-02 2020-07-16 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
CA3031211A1 (en) * 2016-08-02 2018-02-08 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions
US11458146B2 (en) 2017-01-13 2022-10-04 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR101892577B1 (ko) 2017-04-21 2018-08-28 부산대학교 산학협력단 레블라스타틴 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 조성물
CN107286160A (zh) * 2017-06-05 2017-10-24 毛佳婧 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
RU2020110253A (ru) * 2017-08-31 2021-09-30 Ариэль Сайентифик Инновейшнз Лтд Экстракт s. spinosum для лечения жировой болезни печени
BR112022005039A2 (pt) * 2019-09-30 2022-06-21 Durect Corp Tratamento de hepatite alcoólica
EP4171573A4 (en) * 2020-06-26 2025-04-09 Durect Corporation USE OF OXYGENATED CHOLESTEROL SULFATES FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS, NEURODEGENERATIVE DISEASES AND ADDICTION
CN112294827B (zh) * 2020-11-12 2021-12-24 四川大学华西医院 5-胆甾烯 -3β-醇硫酸酯盐的用途
KR102732697B1 (ko) 2021-10-29 2024-11-25 부산대학교 산학협력단 크산틴 유도체를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학적 조성물
WO2024008614A1 (en) * 2022-07-08 2024-01-11 Société des Produits Nestlé S.A. Use of 25-hydroxycholesterol for diabetic treatment and/or prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146223A0 (en) * 1999-04-30 2002-07-25 Arch Dev Corp Steroid derivatives
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
CA2637884A1 (en) 2006-02-13 2007-08-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8003795B2 (en) 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
WO2011077245A2 (en) * 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
EA026683B1 (ru) * 2012-04-12 2017-05-31 Вирджиния Коммонвелт Юниверсити МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА

Also Published As

Publication number Publication date
BR112014025081A2 (pt) 2018-05-08
PT2836502T (pt) 2017-10-27
JP2015512937A (ja) 2015-04-30
ES2641841T3 (es) 2017-11-14
DK2836502T3 (en) 2017-10-23
ZA201406981B (en) 2016-05-25
KR102180485B1 (ko) 2020-11-18
AU2017268646B2 (en) 2019-07-11
JP6125610B2 (ja) 2017-05-10
EP3239163A1 (en) 2017-11-01
BR112014025081B1 (pt) 2020-12-08
CA2867694A1 (en) 2013-10-17
SI2836502T1 (sl) 2017-11-30
AU2013246435B2 (en) 2017-10-05
US20180127457A1 (en) 2018-05-10
PL2836502T3 (pl) 2018-01-31
EA201491859A1 (ru) 2015-02-27
US20150072962A1 (en) 2015-03-12
US20210238219A1 (en) 2021-08-05
JP2021138713A (ja) 2021-09-16
US20190135856A1 (en) 2019-05-09
WO2013154752A1 (en) 2013-10-17
US20160355544A1 (en) 2016-12-08
EP2836502B1 (en) 2017-08-02
CN104220450A (zh) 2014-12-17
HK1202294A1 (en) 2015-09-25
US20200157140A1 (en) 2020-05-21
CN106083976B (zh) 2018-02-09
CN106083976A (zh) 2016-11-09
EP2836502A4 (en) 2015-08-19
HUE035073T2 (en) 2018-05-02
EP2836502A1 (en) 2015-02-18
IN2014KN02366A (https=) 2015-05-01
AU2017268646A1 (en) 2017-12-21
CN104220450B (zh) 2016-07-06
JP2017160213A (ja) 2017-09-14
MX2014012324A (es) 2015-05-11
AU2013246435A1 (en) 2014-10-16
EA026683B1 (ru) 2017-05-31
KR20150013520A (ko) 2015-02-05
JP2019089777A (ja) 2019-06-13
MX357046B (es) 2018-06-22
IL234892B (en) 2019-02-28

Similar Documents

Publication Publication Date Title
AU2017268646B2 (en) A novel cholesterol metabolite, 5-cholesten-3beta-25-diol, disulfate (25HCDS) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis
US11384115B2 (en) Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US8399441B2 (en) Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
HK1202294B (en) A novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis
WO2015034010A1 (ja) 核内受容体肝臓ｘ受容体アゴニスト
EP4397304A1 (en) Composition for treating or preventing obesity or obesity-associated liver disease, comprising verbenone derivatives
EP3353186B1 (en) Highly efficient nrf2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
KR20000049055A (ko) 8(9)-디하이드로에스트라디올 유도체
NZ714082A (en) 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180227

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240916